Hydrating cream and serum for sensitive skin
Impact of a Daily Application of Serum and Cream Containing Glyceryl Eicosapentaenoate and Short-chain Fatty Acids on Skin Hydration: Exploratory Study (COS-PBP-01)
This study is testing different hydrating creams and a serum to see which one helps people with dry, sensitive skin feel more moisturized without causing irritation.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 33 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | SCF Pharma Industry-sponsored |
| Locations | 1 site (Rimouski, Quebec) |
| Trial ID | NCT06219213 on ClinicalTrials.gov |
What this trial studies
This exploratory study evaluates the hydrating effects and potential irritant properties of a 14-day treatment using a serum and three different creams containing glyceryl eicosapentaenoates. Thirty-three participants with dry skin will be divided into three groups, each receiving a different cream formulation while using the same serum. The study will measure skin hydration and redness at baseline and after one and two weeks of treatment to assess the effectiveness of the products. The goal is to determine which formulation provides the best hydration without causing irritation.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 with reported dry skin.
Not a fit: Patients with diagnosed skin diseases requiring drug treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to effective, irritant-free hydration treatments for individuals with sensitive skin.
How similar studies have performed: While similar studies on skin hydration have been conducted, the specific use of glyceryl eicosapentaenoates in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant aged between 18 and 65 years old. * Participant who reports having dry skin. * Available for the entire duration of the study and willing to participate based on the information provided in the informed consent form duly read and signed by the latter. * Participant not presenting intellectual problems likely to limit the validity of consent to participate in the study and compliance with protocol requirements, having the ability to cooperate adequately, understand and observe the instructions of research staff. Exclusion Criteria: * Participant with a skin disease diagnosed by their treating physician and who requires drug treatment.
Where this trial is running
Rimouski, Quebec
- Institut de recherche clinique du littoral (IRCL) — Rimouski, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Samuel Fortin, Ph.D — SCF Pharma
- Study coordinator: Anne-Julie Landry, M.Sc
- Email: ajlandry@scfpharma.com
- Phone: 4183607480
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.